🩺 Prevention of Mother-to-Child Transmission of HIV (PMTCT) – Maternal ART, Infant ARV Prophylaxis, HIV DNA PCR Testing, Breastfeeding vs Formula Feeding, Infant Follow-up📚 Paeds Online – paeds.online
⚕️ OBSERVED STATION · CPSP FORMAT · 8 MINUTES · SEPARATE TABS · PERINATAL COUNSELING SCENARIO
A 26-year-old pregnant woman (G1P0) at 39 weeks of gestation is admitted for delivery. She was diagnosed with HIV infection at 26 weeks of gestation during routine antenatal screening (opt-out testing). She immediately started antiretroviral therapy (ART) – TDF + 3TC + DTG (tenofovir, lamivudine, dolutegravir) at 27 weeks, and has been adherent. Her most recent viral load at 36 weeks was 450 copies/mL (baseline viral load at 26 weeks was 25,000 copies/mL). She is very anxious and asks:
"Doctor, I am HIV positive. I have been taking my medicines since 27 weeks. I am so scared that my baby will get AIDS. What is the chance that my baby will be infected? How can we protect my baby after birth? Can I breastfeed? What tests will my baby need? Will my baby need medicines? Please tell me everything."
The mother has no other medical problems. She is adherent to ART. She asks about delivery mode (vaginal vs Cesarean section).
Task for the candidate: You are the pediatrician. Counsel the mother about the risk of mother-to-child transmission (MTCT) of HIV, the importance of maternal viral load, the need for infant ARV prophylaxis (nevirapine or AZT), HIV diagnostic testing (HIV DNA PCR at birth, 6 weeks, 12 weeks, 6 months), feeding options (exclusive formula vs exclusive breastfeeding), the importance of maternal ART adherence, and the long-term follow-up of the infant. The examiner will observe your interaction and communication skills.
💡 Examiner instruction (interactive – observed counseling):
• The candidate must demonstrate empathy, active listening, and clear, non-judgmental communication.
• Address the mother's fear first ("Thank you for trusting me with this information. You have done the right thing by starting treatment. We have very effective ways to protect your baby").
• Explain that with proper ART and infant prophylaxis, the risk of transmission is less than 1% if maternal viral load is undetectable at delivery. With a viral load of 450 copies/mL, the risk is low (~1-2%), but not zero.
• Discuss the need for infant ARV prophylaxis (nevirapine or AZT) for 4-6 weeks regardless of viral load.
• Discuss HIV diagnostic testing for the infant: HIV DNA PCR at birth, 6 weeks, 12 weeks, and 6 months (or as per national guidelines).
• Discuss feeding options in detail (exclusive formula vs exclusive breastfeeding with maternal ART). In resource-rich settings, formula is recommended; in resource-limited settings, exclusive breastfeeding with ART is recommended.
• Discuss mode of delivery: If viral load >1000 copies/mL near delivery, elective Cesarean section is recommended; if <1000 copies/mL (like this mother), vaginal delivery is safe.
• Emphasize that maternal ART adherence is the most important factor to prevent transmission and to keep the mother healthy for her child.
• The examiner will then ask the candidate specific questions from the Q&A tab.
💬 Model Counseling Script – Candidate's Interaction with Mother
🗣️ Candidate's structured counseling (to be delivered to the mother):
1. Acknowledge, empathize, and reduce self-blame:
“Thank you for sharing this with me. I can see how worried you are. Please know that this is not your fault. The most important thing is that you are taking your medicines, and that is the best thing you can do to protect your baby. You are doing everything right.”
2. Explain the risk of transmission and the effect of ART:
“Without any treatment, a mother with HIV has about a 25% chance of passing the virus to her baby during pregnancy, delivery, or breastfeeding. But with proper treatment, we can reduce that risk to less than 1% – and in many cases, to zero. Your viral load at 36 weeks was 450 copies/mL. That is very low. If your viral load is undetectable (less than 50 copies/mL) at delivery, the risk is less than 1%. If it is still detectable but low (like now), the risk is still very low – around 1-2%. You have already reduced your viral load dramatically from 25,000 to 450. Continue your medicines – you are doing great.”
3. Discuss mode of delivery:
“Because your viral load is below 1000 copies/mL, you do not need a Cesarean section for HIV. You can have a vaginal delivery safely. If the viral load were above 1000 copies/mL near delivery, we would recommend a planned C-section to reduce the risk. We will check your viral load again at delivery to be sure.”
4. Discuss infant ARV prophylaxis (baby’s medicine):
“After the baby is born, the baby will need to take HIV medicine (prophylaxis) for 4 to 6 weeks. This medicine will protect the baby from any virus that might have been transmitted during delivery. The medicine is usually nevirapine syrup given once daily, or sometimes AZT twice daily. It is safe, and most babies have no side effects. Your baby will also receive vitamin K and eye ointment just like any other baby.”
5. Discuss feeding options – VERY IMPORTANT:
“Now, let me explain about feeding. HIV can be transmitted through breast milk. So we have two options, and we will decide together based on your situation:
• Option 1: Exclusive formula feeding. This is recommended in many countries where clean water and formula are available. If you choose formula, the baby has almost zero risk of getting HIV from feeding. You must use only formula, not mix with breast milk. And you need to prepare it safely with boiled water.
• Option 2: Exclusive breastfeeding with ART. In some countries where clean water is not always available, exclusive breastfeeding (no other foods or liquids) for 6 months, while you continue your ART, is recommended. The risk of transmission through breast milk is very low (less than 1%) if you are on ART and your viral load is undetectable. But you must not mix breast milk and formula – that increases risk. You must stop breastfeeding completely at 6-12 months.
“What is available in your home? Do you have clean water? Can you afford formula?” (Wait for mother’s response). “I recommend exclusive formula feeding because it eliminates the risk completely. But I will support whatever you choose.”
6. Discuss HIV testing for the baby:
“The baby will need several blood tests for HIV. We use a special test called HIV DNA PCR. We will test at:
• At birth (within 48 hours).
• At 6 weeks of age.
• At 12 weeks of age.
• At 6 months of age.
The baby is not diagnosed at birth – we need to repeat the tests because the mother’s antibodies pass to the baby and can stay for up to 18 months. But the DNA PCR test looks for the virus itself, so it is very accurate after 6 weeks. If all tests are negative, your baby is HIV-free.”
7. Discuss cotrimoxazole (Septrin) prophylaxis:
“Your baby will also need a medicine called cotrimoxazole (Septrin) starting at 4-6 weeks of age. This prevents certain infections. The baby will take it until we are sure the baby is HIV-negative (usually until 6-12 months after breastfeeding stops).”
8. Emphasize maternal ART adherence and follow-up:
“The most important thing you can do to keep your baby healthy is to continue taking your ART medicines every day without missing a dose. Not only does this keep your viral load undetectable, which protects the baby, but it also keeps you healthy so you can take care of your child. We will support you.”
9. Summarize and close:
“To summarize: Your baby has a very low risk (less than 2%, probably much less) of getting HIV because you are on treatment. The baby will take HIV medicine for 4-6 weeks after birth. We will do HIV DNA PCR tests at birth, 6 weeks, 12 weeks, and 6 months. We will discuss feeding – I recommend exclusive formula feeding if possible. You must continue your ART. You are doing a wonderful job. We are here to support you.”
📌 Examiner observation points (communication skills):
• Did the candidate demonstrate empathy and avoid judgment or stigma?
• Did they explain transmission risk correctly (25% without treatment, <1% with treatment)?
• Did they discuss the importance of maternal viral load?
• Did they explain infant ARV prophylaxis (nevirapine/AZT) for 4-6 weeks?
• Did they discuss HIV DNA PCR testing schedule correctly?
• Did they provide balanced, evidence-based counseling on feeding (formula vs breastfeeding)?
• Did they discuss cotrimoxazole prophylaxis?
• Did they discuss mode of delivery based on viral load?
• Did they emphasize maternal ART adherence as the most important factor?
• Did they provide a clear follow-up plan and offer support?
🔍 Examiner Questions (after counseling) – Click to reveal model answers
❓ Q1 (Examiner): “What is the risk of mother-to-child transmission of HIV without any intervention? How much does ART reduce this risk?”
✅ Candidate's answer:
• Without any intervention: Transmission risk is approximately 25-30% (15-20% during pregnancy/delivery, plus 10-15% through breastfeeding).
• With ART during pregnancy and delivery + infant prophylaxis + avoidance of breastfeeding (or exclusive breastfeeding with ART): Risk is less than 1-2% (often <0.5% if maternal viral load is undetectable at delivery).
• Key interventions that reduce MTCT:
- Maternal ART during pregnancy (especially before delivery).
- Intrapartum IV zidovudine (if maternal viral load >1000 copies/mL).
- Infant ARV prophylaxis (nevirapine or AZT for 4-6 weeks).
- Avoidance of breastfeeding (or exclusive breastfeeding with ART).
- Elective Cesarean section if viral load >1000 copies/mL.
❓ Q2 (Examiner): “What infant ARV prophylaxis is recommended for this baby? For how long? What dose of nevirapine is used?”
✅ Candidate's answer:
• Recommended regimen depends on maternal ART and viral load, but standard for low-risk (mother on ART with viral load <1000):
- Nevirapine (NVP) syrup daily for 4-6 weeks.
- Dose: 2 mg/kg once daily for 2 weeks, then 4 mg/kg once daily for 2-4 weeks (or as per local protocol).
- Alternative: Zidovudine (AZT) 4 mg/kg twice daily for 4-6 weeks.
• For high-risk infants (mother not on ART, viral load >1000, or late presentation): Dual or triple prophylaxis (e.g., AZT + NVP for 6 weeks, or AZT + 3TC + NVP).
• This baby (mother on ART, viral load 450): Standard risk → Nevirapine or AZT monotherapy for 4-6 weeks is sufficient.
• Start: Within 6-12 hours of birth (ideally as soon as possible, but definitely within 48 hours).
• Continue for 4-6 weeks (until HIV DNA PCR at 6 weeks is negative).
❓ Q3 (Examiner): “When should HIV testing be performed on this infant? What test is used? When can you definitively exclude HIV infection?”
✅ Candidate's answer:
• Test:HIV DNA PCR (detects proviral DNA; not affected by maternal antibodies). Do NOT use HIV antibody tests (ELISA) in infants <18 months (maternal antibodies persist).
• Testing schedule (WHO/CDC guidelines):
1️⃣ At birth (within 48 hours) – detects in utero transmission.
2️⃣ At 6 weeks of age – most important; detects intrapartum transmission.
3️⃣ At 12 weeks (3 months) – confirms negative status.
4️⃣ At 6 months (if still breastfeeding) or 4-6 weeks after complete cessation of breastfeeding – to rule out breastfeeding transmission.
• Definitive exclusion of HIV infection:
- Two negative HIV DNA PCR tests (one at ≥6 weeks and another at ≥12 weeks) in a non-breastfed infant.
- In a breastfed infant, repeat testing 4-6 weeks after complete cessation of breastfeeding (usually at 12-18 months).
• HIV antibody test (ELISA) can be done at 18 months to confirm seroreversion (loss of maternal antibodies).
❓ Q4 (Examiner): “Should this mother have a Cesarean section or vaginal delivery? What is the indication for elective C-section in HIV-positive women?”
✅ Candidate's answer:
• Elective Cesarean section (planned C-section) is recommended if maternal viral load is >1000 copies/mL near delivery.
• This mother has viral load 450 copies/mL (<1000). Therefore, vaginal delivery is safe and C-section is not indicated for HIV alone.
• Additional benefits of C-section when indicated: Reduces intrapartum transmission by 50-70% when performed before rupture of membranes and before labor.
• If viral load is undetectable (<50 copies/mL), risk of intrapartum transmission is extremely low (<0.5%), and C-section offers no additional benefit.
• If membranes rupture >4 hours before delivery, the protective effect of C-section is reduced.
• Intrapartum IV zidovudine (AZT) is recommended for all HIV-positive women regardless of viral load if they are not on ART or have detectable viral load. If mother is on ART with viral load <50, IV AZT is not necessary.
❓ Q5 (Examiner): “Does this infant need cotrimoxazole (Septrin) prophylaxis? If so, when should it be started and for how long?”
✅ Candidate's answer:
• Yes, all HIV-exposed infants (born to HIV-positive mothers) should receive cotrimoxazole prophylaxis.
• Start: At 4-6 weeks of age (or at 6 weeks if the infant is on nevirapine prophylaxis – can give together).
• Dose:2.5 mL (100 mg/200 mg per 5 mL) once daily for infants <6 months, or weight-based dosing (trimethoprim 5 mg/kg/day).
• Duration:
- If infant is HIV-negative (confirmed by HIV DNA PCR after cessation of breastfeeding): Stop cotrimoxazole after 4-6 weeks of negative confirmatory test and after breastfeeding has stopped (usually around 6-12 months).
- If infant is HIV-positive: Continue cotrimoxazole indefinitely (lifelong).
• Purpose: Prevents Pneumocystis jirovecii pneumonia (PCP) – the most common opportunistic infection in HIV-infected infants, which has high mortality.
❓ Q6 (Examiner): “What are the WHO recommendations for infant feeding in HIV-exposed infants? How would you counsel this mother?”
✅ Candidate's answer:
• WHO recommendations (individualized counseling):
1️⃣ If the mother can afford and safely prepare formula (clean water, fuel, health system support):Exclusive formula feeding is recommended (zero risk of HIV transmission through feeding).
2️⃣ If formula feeding is not safe (no clean water, risk of diarrhea, stigma):Exclusive breastfeeding with maternal ART for 6 months, followed by rapid cessation and introduction of complementary foods. The risk of transmission through breast milk is <1% if mother is on ART with undetectable viral load.
• Important rules:
- Do NOT mix breast milk and formula (mixed feeding increases risk of transmission due to gut irritation).
- Do NOT give any other liquids or foods in the first 6 months.
- Breastfeeding should stop completely at 6-12 months (not gradually).
- Continue maternal ART throughout breastfeeding.
• For this mother (viral load 450, may become undetectable): If she has clean water and can afford formula, I would recommend exclusive formula feeding to eliminate feeding-related risk. If not, exclusive breastfeeding with ART is a safe alternative.
❓ Q7 (Examiner): “What is the most important factor to prevent MTCT? How would you counsel the mother about ART adherence?”
✅ Candidate's answer:
• The single most important factor is maintaining an undetectable viral load through strict adherence to ART.
• “You must take your medicines every day at the same time without missing any doses. If you miss doses, the virus can become resistant and your viral load will go up, which increases the risk of transmission to your baby.”
• “If you have side effects (nausea, dizziness, rash), tell us – we can help manage them or change your medicines. Do NOT stop taking them on your own.”
• “We will check your viral load regularly – at delivery, at 6 weeks postpartum, and then every 3-6 months.”
• “Keep your clinic appointments. Some clinics offer directly observed therapy (DOT) or adherence support groups.”
• “Staying on ART is not just for your baby – it is for your own health. With ART, you can live a long, healthy life and raise your child.”
❓ Q8 (Examiner): “If this mother chooses to breastfeed exclusively for 6 months, when is the final HIV test for the baby? When can you declare the baby HIV-negative?”
✅ Candidate's answer:
• If the baby is breastfed, final HIV testing should be performed 4-6 weeks after complete cessation of breastfeeding (to account for the window period).
• Timeline:
- Breastfeed exclusively for 6 months, then stop completely.
- Wait 4-6 weeks after stopping breastfeeding (at 7-7.5 months of age).
- Perform HIV DNA PCR at that time.
- If negative, repeat at 12 months (or 18 months) for confirmation.
• Definitive exclusion of HIV in a breastfed infant requires:
- Two negative HIV DNA PCR tests, with at least one performed ≥6 weeks after complete cessation of breastfeeding.
- HIV antibody test (ELISA) negative at ≥18 months (to confirm loss of maternal antibodies).
• If the mother continues breastfeeding beyond 6 months, the baby needs ongoing testing every 3 months.
❓ Q9 (Examiner): “What are the potential side effects of nevirapine in an infant? How would you monitor?”
✅ Candidate's answer:
• Nevirapine is generally well-tolerated in infants, but side effects can include:
- Rash (maculopapular, mild – most common).
- Hepatotoxicity (elevated liver enzymes, rare in infants at prophylactic doses).
- Nausea, vomiting, diarrhea.
- Severe rash (Stevens-Johnson syndrome) – very rare.
• Monitoring:
- Clinical monitoring: check for rash, jaundice, poor feeding, vomiting.
- Liver function tests (ALT, AST) are not routinely required for prophylaxis in healthy infants but should be checked if symptoms develop or if the infant has other risk factors.
- If rash develops, stop nevirapine and consult a specialist; alternative prophylaxis (AZT) can be used.
• Most infants have no significant side effects.
❓ Q10 (Examiner): “Can this infant receive routine immunizations? Are there any contraindications?”
✅ Candidate's answer:
• All routine inactivated vaccines (DPT, HepB, Hib, IPV, PCV, rotavirus) are safe and recommended on the standard schedule.
• Live vaccines:
- BCG: Should be given at birth (or as soon as possible) to HIV-exposed infants UNLESS the infant is symptomatic or severely immunocompromised. If the infant has confirmed HIV infection with severe immunosuppression (low CD4%), BCG is contraindicated due to risk of disseminated BCG disease. Most HIV-exposed infants are not known to be infected at birth, so BCG is given. This infant should receive BCG at birth.
- Measles, MMR, varicella: Can be given at the standard ages (9 months, 12 months, etc.) if the infant is not severely immunocompromised. For HIV-infected infants with severe immunosuppression, these vaccines are contraindicated.
- Rotavirus vaccine: Can be given to HIV-exposed infants (it is a live attenuated vaccine but generally safe).
• Important: Do not delay immunizations while waiting for HIV test results unless the infant is symptomatic or known to have advanced HIV disease.
❓ Q11 (Examiner): “What long-term follow-up is needed for this infant, assuming all HIV tests are negative?”
✅ Candidate's answer:
• HIV-uninfected, HIV-exposed infants (HEU – HIV-exposed uninfected) still need long-term monitoring because they may have subtle health differences compared to unexposed infants.
• Follow-up plan:
1️⃣ Regular well-child visits with growth and developmental monitoring.
2️⃣ HIV testing at 18 months (HIV antibody test) to confirm seroreversion (loss of maternal antibodies).
3️⃣ Immunizations on schedule; no special precautions.
4️⃣ Monitor for signs of HIV infection (unexplained fever, recurrent infections, failure to thrive, lymphadenopathy, parotitis, oral thrush) even if previous PCRs were negative – very rare but possible.
5️⃣ Counseling for the mother – ensure she stays on ART and attends her own follow-up.
6️⃣ Monitor for possible increased risk of certain infections – some studies show HEU infants have higher rates of severe bacterial infections; ensure timely immunizations and seek care early for fevers.
7️⃣ Developmental screening – some HEU infants may have subtle neurodevelopmental delays; early intervention if needed.
❓ Q12 (Examiner): “When and how should the mother disclose her HIV status to this child as the child grows up? What about disclosure of the child’s own HIV status if infected?”
✅ Candidate's answer:
• Disclosure is a gradual process, not a single event.
• For the child’s own status (if HIV-positive):
- Ages 0-5 years: Do not disclose diagnosis to child. Use terms like “medicines to keep you healthy.”
- Ages 6-9 years: Begin age-appropriate disclosure (e.g., “You have a virus in your blood, and the medicine keeps it quiet”).
- Ages 10-14 years: Full disclosure of HIV diagnosis, mode of transmission, importance of adherence, and prevention of transmission to others.
- Adolescents: Prepare for transition to adult care, discuss sexual health, prevention of transmission, and status disclosure to partners.
• Disclosure of maternal status to the child (if child is HIV-negative):
- Usually deferred until adolescence (12-14 years) unless the child asks questions.
- The mother should be supported by a counselor.
- The child should be informed before becoming sexually active so they can take preventive measures.
• If the child is HIV-negative, the mother does not need to disclose her status early; she can explain that she takes medicines for her own health. When the child is mature enough (adolescence), she can have a full discussion.
🗣️ Examiner's probing / high-yield points (PMTCT):
• "What is the transmission risk without any intervention?" → 25-30%. With ART + infant prophylaxis → <1-2%.
• "What infant prophylaxis is given?" → Nevirapine or AZT for 4-6 weeks.
• "What test is used to diagnose HIV in an infant?" → HIV DNA PCR (not antibody test).
• "When is elective C-section indicated?" → Viral load >1000 copies/mL near delivery.
• "Is breastfeeding safe if mother is on ART?" → Exclusive breastfeeding with ART has very low risk (<1%) if viral load undetectable.
• "What is cotrimoxazole for?" → Prevents PCP pneumonia; given to all HIV-exposed infants from 4-6 weeks.
• "What is the most important factor to prevent transmission?" → Maternal ART adherence to maintain undetectable viral load.
📘 Prevention of Mother-to-Child Transmission (PMTCT) – Core Revision for TOACS
🔍 Transmission Risk Without intervention: 25-30%. With ART + infant prophylaxis + formula feeding: <1-2%. Risk directly correlates with maternal viral load (undetectable → <0.5%).
💊 Infant ARV Prophylaxis Nevirapine (2 mg/kg → 4 mg/kg daily) or AZT (4 mg/kg twice daily) for 4-6 weeks, started within 6-12 hours of birth.
🩺 HIV Testing HIV DNA PCR at birth, 6 weeks, 12 weeks, and 6 months (or 4-6 weeks after breastfeeding cessation). Do NOT use antibody tests in infants <18 months.
🍼 Feeding Exclusive formula feeding (zero risk) if safe and affordable. If not, exclusive breastfeeding with maternal ART for 6 months (risk <1%). No mixed feeding.
💊 Cotrimoxazole Start at 4-6 weeks to prevent PCP. Continue until HIV excluded (after breastfeeding stops).
🤱 Mode of Delivery Vaginal delivery safe if viral load <1000 copies/mL. Elective C-section if viral load >1000 copies/mL near delivery.
⭐ High-yield pearls for TOACS (PMTCT Counseling):
• Risk with optimal management: <1% (often <0.5%).
• Infant ARV prophylaxis: Nevirapine or AZT for 4-6 weeks, start within 6-12 hours.
• HIV DNA PCR at birth, 6 weeks, 12 weeks, and after breastfeeding stops.
• Formula feeding eliminates feeding-related risk; exclusive breastfeeding with ART is the alternative.
• Cotrimoxazole from 4-6 weeks until HIV excluded.
• Maternal ART adherence is the single most important factor.
• Do NOT use HIV antibody tests in infants <18 months.